Hepatitis C Antiviral Resistance in African-Americans
Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis C (Virahep-C)
Sponsor: Hoffmann-La Roche
A PHASE3 clinical study on Hepatitis C, this trial is completed. The trial is conducted by Hoffmann-La Roche and has accumulated 7 data snapshots since 2002. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Oct 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Oct 2022 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Aug 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Aug 2017 [monthly]
Completed PHASE3
First recorded
Aug 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hoffmann-La Roche
- National Cancer Institute (NCI)
- National Center for Advancing Translational Sciences (NCATS)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- National Institute on Minority Health and Health Disparities (NIMHD)
For direct contact, visit the study record on ClinicalTrials.gov .